基于TCGA与GTEx数据库分析AEBP1基因在不同分型胶质瘤中的表达及对预后的影响

Objective: To explore the expressions of adipocyte enhancer binding protein 1 (AEBP1) gene and its isoforms in different types of gliomas, and the influence of AEBP1 gene on the prognosis of patients with different types of gliomas. Methods: We used the GEPIA2 visual network analysis tool to analyze AEBP1 gene expression levels in the tumor tissues of glioblastomas (GBM, including classical, mesenchymal, neural, and proneural ones) and low-grade gliomas (LGG, including astrocytoma, oligoastrocytoma, oligodendroglioma) in the TCGA database and normal human tissue samples in the TCGA and GTEx databases by one-way ANOVA. The distribution trend of isoforms of AEBP1 gene in gliomas was analyzed using the violin plot. The Kaplan-Meier survival curve was drawn and the Logrank test was used to analyze the influence of AEBP1 gene expression in GBM and LGG tumor tissues on the prognosis of glioma patients. Results: The expression of AEBP1 in the tumor tissues of overall GBM and the four types of GBM was higher than that in the normal control tissues (P<0.05). The expression of AEBP1 in astrocytoma and oligodendrocyte astrocytoma tumor tissues was higher than that in normal control tissues (P<0.05). There were nine isoforms of AEBP1 gene in GBM and LGG, and the expression level in GBM was higher. The overall survival (OS) of the AEBP1 low expression group of GBM patients and the proneuronal GBM patients was better than that of the high expression group (P<0.05). The OS and progression-free survival of LGG patients and the AEBP1 low-expression group of astroglioma were better than those of the high-expression group (P<0.05). Conclusion: AEBP1 has an important clinical value in the pathogenesis and development of GBM and LGG, and thus can be used as a diagnostic marker and a candidate gene for targeted therapy.